FutureGen Biopharmaceutical (Beijing) Co., Ltd
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma | mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT07758491 | |
| A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors | Claudin 18.2; Solid Tumor Malignancies | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-15 | NCT07704866 | |
| A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors | Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-03 | NCT07623707 | |
| A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 3 | 2026-02-04 | NCT07383922 | |
| M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2024-02-28 | NCT06177041 |